KRAS and lung cancer: However, the use of MEKi as a single agent or in combination with other clinical drugs has failed to demonstrate significant survival outcomes in KRAS-driven lung cancer, partly because of reactivation of the MAPK pathway component or reduced dominant intratumoral T cell clones (8, 9).